In patients treated with NeoRecormon, this incidence is 7% compared to 4% in controls; this is not associated with any increase in thromboembolic mortality compared with controls.
NeoRecormon’ iga ravitud patsientidel oli see esinemissagedus 7% võrreldes 4% - ga kontrollgrupis; see ei ole seotud trombemboolse suremuse suurenemisega võrreldes kontrollisikutega.